News | April 11, 2025
US court lifts launch restrictions on Sun Pharma's autoimmune drug
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Sun Pharma has been involved in a patent infringement case with Incyte Corporation over LEQSELVI
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Antibe Therapeutics is a clinical-stage biotechnological company developing novel drugs primarily focusing on reducing pain and inflammation
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
The company will also share results in two additional posters for deuruxolitinib
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
